| |
Pre-infection
|
Fiebig stages I–II
|
Fiebig stages III–V
|
Chronic
|
P valuea
|
|---|
|
Fiebig stages I–II
|
Fiebig stages III–V
|
Chronic
|
|---|
|
Number of participants
|
70
|
60
|
15
|
33
|
N/A
|
N/A
|
N/A
|
|
Female, N (%)
|
70 (100%)
|
60 (100%)
|
15 (100%)
|
32 (97%)
|
1.000
|
1.000
|
0.143
|
|
Age in years
|
21.1 (19.8–22.1)
|
21.2 (19.9–22.5)
|
22.5 (20.8–23.7)
|
22.9 (21.4–24.3)
|
0.508
|
0.039
|
< 0.001
|
|
Viral load (log10 copies/mL)
|
N/A
|
4.20 (3.50–4.92)
|
6.26 (4.88–7.20)
|
3.60 (3.04–4.31)
|
N/A
|
N/A
|
N/A
|
|
CD4+ T cell counts (cells/μL)
|
891 (751–1047)
|
763 (538–911)
|
444 (367–553)
|
599 (470–756)
|
< 0.001
|
< 0.001
|
< 0.001
|
- Values for age, viral load, and CD4+ T cell counts are medians and interquartile ranges
- aStatistical test used: Wilcoxon rank-sum test (Mann-Whitney U test) was used to compare the differences in age and CD4+ T cell counts between pre-infection and post-infection time points. Chi-square test was used to assess the differences in gender distribution
